Should I Buy COCP? COCP 2026 Analysis

Should You Buy Cocrystal Pharma Inc (COCP) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

1.000

1 Day change

-1.96%

52 Week Range

2.670

Analysis Updated At

2026/01/28

COCP is not a good buy right now for a beginner long-term investor with $50k–$100k. The stock is in a bearish downtrend with weakening momentum, the company remains pre-revenue, and the latest quarter showed widening losses. Despite strong insider buying, the setup does not currently offer a favorable long-term entry for an impatient investor.

Technical Analysis

Price/Trend: Bearish structure with moving averages stacked negatively (SMA_200 > SMA_20 > SMA_5), indicating a sustained downtrend. Momentum: MACD histogram is negative (-0.00975) and negatively expanding, suggesting downside momentum is strengthening. RSI: RSI_6 at 33.5 is near oversold but still classified as neutral here—this can precede bounces, but it is not a confirmed reversal signal. Levels: Current price ~1.02 is sitting right above S1 (1.012). A clean break below S1 increases risk of a move toward S2 (0.967). Upside is capped by pivot (1.085) then R1 (1.157). Pattern-based outlook: The provided pattern stats show limited expected upside (only ~2.06% in the next month), which is not compelling versus the technical risk. Intellectia Proprietary Trading Signals: - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock recently.

Options Data

Positive Catalysts

Insider activity: Insiders are Buying, with buying amount up ~469.57% over the last month, which can be a bullish confidence indicator.
Potential technical bounce: RSI near the low-30s and price sitting near support (S1 ~1.012) can sometimes trigger short-lived rebounds.

Neutral/Negative Catalysts

Business fundamentals: Still effectively pre-revenue, so returns depend heavily on future clinical/business milestones that are not reflected in current financial traction.

Financial Performance

Latest quarter (2025/Q3): Revenue was 0 (no YoY growth), while losses widened. Net income fell to -$2.049M (down 58.51% YoY) and EPS declined to -$0.19 (down 61.22% YoY). Overall, the quarter shows deterioration in profitability without revenue growth, which is unfavorable for long-term accumulation right now.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating trend or price target changes were provided in the data. Without current Wall Street coverage details, there is no visible external consensus support to offset the bearish technicals and weak financial trajectory.

1 Analyst Rating

Wall Street analysts forecast COCP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COCP is 10 USD with a low forecast of 10 USD and a high forecast of 10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.020

Low

Averages

High

Current: 1.020

Low

Averages

High

H.C. Wainwright

Buy

downgrade

$7 -> $6

AI Analysis

2025-06-21

Reason